In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Dyne Therapeutics Inc (NASDAQ: DYN) closed at $7.04 up 0.86% from its previous closing price of $6.98. In other words, the price has increased by $0.86 from its previous closing price. On the day, 1.35 million shares were traded. DYN stock price reached its highest trading level at $7.14 during the session, while it also had its lowest trading level at $6.755.
Ratios:
For a deeper understanding of Dyne Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.60 and its Current Ratio is at 15.60. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on March 12, 2025, initiated with a Outperform rating and assigned the stock a target price of $50.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $50.
On December 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $46.Robert W. Baird initiated its Outperform rating on December 13, 2024, with a $46 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 13 ’25 when Friedl-Naderer Johanna sold 143 shares for $12.12 per share. The transaction valued at 1,733 led to the insider holds 96,057 shares of the business.
Scalzo Richard William sold 1,343 shares of DYN for $15,283 on Mar 11 ’25. The SVP, Head of Finance & Admin. now owns 122,330 shares after completing the transaction at $11.38 per share. On Mar 11 ’25, another insider, Beskrovnaya Oxana, who serves as the Chief Scientific Officer of the company, sold 2,153 shares for $11.38 each. As a result, the insider received 24,501 and left with 195,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DYN now has a Market Capitalization of 796371840 and an Enterprise Value of 178094352.
Stock Price History:
The Beta on a monthly basis for DYN is 1.36, which has changed by -0.7232704 over the last 52 weeks, in comparison to a change of 0.059571505 over the same period for the S&P500. Over the past 52 weeks, DYN has reached a high of $47.45, while it has fallen to a 52-week low of $6.36. The 50-Day Moving Average of the stock is -42.09%, while the 200-Day Moving Average is calculated to be -74.29%.
Shares Statistics:
For the past three months, DYN has traded an average of 2.30M shares per day and 3390440 over the past ten days. A total of 102.32M shares are outstanding, with a floating share count of 87.33M. Insiders hold about 22.80% of the company’s shares, while institutions hold 80.95% stake in the company. Shares short for DYN as of 1743379200 were 11341719 with a Short Ratio of 4.93, compared to 1740700800 on 11667343. Therefore, it implies a Short% of Shares Outstanding of 11341719 and a Short% of Float of 11.690000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
